PMID- 26505750
OWN - NLM
STAT- MEDLINE
DCOM- 20160620
LR  - 20181202
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 10
IP  - 10
DP  - 2015
TI  - Sevoflurane Preconditioning Reduces Intestinal Ischemia-Reperfusion Injury: Role 
      of Protein Kinase C and Mitochondrial ATP-Sensitive Potassium Channel.
PG  - e0141426
LID - 10.1371/journal.pone.0141426 [doi]
LID - e0141426
AB  - Ischemic preconditioning (IPC) has been considered to be a potential therapy to 
      reduce ischemia-reperfusion injury (IRI) since the 1980s. Our previous study 
      indicated that sevoflurane preconditioning (SPC) also reduced intestinal IRI in 
      rats. However, whether the protective effect of SPC is similar to IPC and the 
      mechanisms of SPC are unclear. Thus, we compared the efficacy of SPC and IPC 
      against intestinal IRI and the role of protein kinase C (PKC) and mitochondrial 
      ATP-sensitive potassium channel (mKATP) in SPC. A rat model of intestinal IRI was 
      used in this study. The superior mesenteric artery (SMA) was clamped for 60 min 
      followed by 120 min of reperfusion. Rats with IPC underwent three cycles of SMA 
      occlusion for 5 min and reperfusion for 5 min before intestinal ischemia. Rats 
      with SPC inhaled sevoflurane at 0.5 minimum alveolar concentration (MAC) for 30 
      min before the intestinal ischemic insult. Additionally, the PKC inhibitor 
      Chelerythrine (CHE) or mKATP inhibitor 5-Hydroxydecanoic (5-HD) was injected 
      intraperitoneally before sevoflurane inhalation. Both SPC and IPC ameliorated 
      intestinal IRI-induced histopathological changes, decreased Chiu's scores, 
      reduced terminal deoxyribonucleotide transferase-mediated dUTP nick end labeling 
      (TUNEL) positive cells in the epithelium, and inhibited the expression of 
      malondialdehyde (MDA) and tumor necrosis factor-alpha (TNF-alpha). These protective 
      effects of SPC were similar to those of IPC. Pretreatment with PKC or mKATP 
      inhibitor abolished SPC-induced protective effects by increasing Chiu's scores, 
      down-regulated the expression of Bcl-2 and activated caspase-3. Our results 
      suggest that pretreatment with 0.5 MAC sevoflurane is as effective as IPC against 
      intestinal IRI. The activation of PKC and mKATP may be involved in the protective 
      mechanisms of SPC.
FAU - Liu, Chuiliang
AU  - Liu C
AD  - Department of Anesthesiology, ChanCheng Center Hospital, Foshan, Guangdong, 
      China.
FAU - Liu, Yanhui
AU  - Liu Y
AD  - Department of Anesthesiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen 
      University, Guangzhou, Guangdong, China.
FAU - Shen, Zhiwen
AU  - Shen Z
AD  - Department of Anesthesiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen 
      University, Guangzhou, Guangdong, China.
FAU - Miao, Liping
AU  - Miao L
AD  - Department of Anesthesiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen 
      University, Guangzhou, Guangdong, China.
FAU - Zhang, Kun
AU  - Zhang K
AD  - Department of Anesthesiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen 
      University, Guangzhou, Guangdong, China.
FAU - Wang, Fei
AU  - Wang F
AD  - Department of Anesthesiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen 
      University, Guangzhou, Guangdong, China.
FAU - Li, Yujuan
AU  - Li Y
AD  - Department of Anesthesiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen 
      University, Guangzhou, Guangdong, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151027
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Benzophenanthridines)
RN  - 0 (KATP Channels)
RN  - 0 (Methyl Ethers)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 38LVP0K73A (Sevoflurane)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - E3B045W6X0 (chelerythrine)
RN  - EC 2.7.11.13 (Protein Kinase C)
SB  - IM
MH  - Animals
MH  - Benzophenanthridines/administration & dosage
MH  - Intestinal Mucosa/*metabolism
MH  - Intestines/drug effects/pathology
MH  - Ischemic Preconditioning
MH  - KATP Channels/antagonists & inhibitors/*metabolism
MH  - Malondialdehyde/metabolism
MH  - Mesenteric Artery, Superior/drug effects/pathology
MH  - Methyl Ethers/administration & dosage
MH  - Mitochondria/drug effects/pathology
MH  - Protein Kinase C/antagonists & inhibitors/*metabolism
MH  - Rats
MH  - Reperfusion Injury/*drug therapy/pathology
MH  - Sevoflurane
MH  - Tumor Necrosis Factor-alpha/biosynthesis
PMC - PMC4624762
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2015/10/28 06:00
MHDA- 2016/06/21 06:00
PMCR- 2015/10/27
CRDT- 2015/10/28 06:00
PHST- 2015/05/12 00:00 [received]
PHST- 2015/09/06 00:00 [accepted]
PHST- 2015/10/28 06:00 [entrez]
PHST- 2015/10/28 06:00 [pubmed]
PHST- 2016/06/21 06:00 [medline]
PHST- 2015/10/27 00:00 [pmc-release]
AID - PONE-D-15-19887 [pii]
AID - 10.1371/journal.pone.0141426 [doi]
PST - epublish
SO  - PLoS One. 2015 Oct 27;10(10):e0141426. doi: 10.1371/journal.pone.0141426. 
      eCollection 2015.